Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS

NCT04482699 is registered in ClinicalTrials.gov with Rapa Therapeutics LLC as lead sponsor.

NCT NCT04482699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04482699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS
Lead sponsor
Rapa Therapeutics LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
December 30, 2020
Completion date
September 13, 2021
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe covid-19 disease